Autoinjector is now available. Learn more

You had searched for:

There were no results matching the query.

You can also browse the topics below to find what you are looking for.

Patient Profiles


Maura

Anna

Need help answering a question?

Support Services

  1. Download the Prescription and Service Request Form (PSRF)
  2. Fax the completed form to Shared Solutions® at 1-844-257-6127

Patients can call 1-800-887-8100, Monday–Friday, 8 am–6 pm CT.

Frequently Asked Questions

Side effects of AJOVY

HALO phase 3 clinical trials

The most common adverse reactions reported in ≥2% of patients were injection-site reactions (including injection-site pain, injection-site induration, and injection-site erythema).1

  • <1% of patients experienced constipation vs <1% for placebo2
  • ≤2% of patients discontinued due to adverse events in the AJOVY and placebo treatment arms2
  • <1% of patients in both phase 3 trials developed antibodies to AJOVY1

Long-Term Extension study—continuation of the HALO trials*

The most common adverse reactions reported by >6% of patients were injection-site reactions (including injection-site induration, pain, erythema, hemorrhage, and pruritus).3

  • No new safety signals were identified2
  • 6% of patients discontinued due to lack of efficacy or adverse events2
    • Discontinuation rates were comparable for both quarterly (7%) and monthly (5%) dosing2

*The primary purpose of the Long-Term Extension study was the collection of long-term safety data. Therefore, the study was not placebo-controlled.

Please read the full Important Safety Information, and the full Prescribing Information.

SEE THE SAFETY PROFILE IN CLINICAL TRIALS FOR AJOVY

Need help answering a question?

Support Services

  1. Download the Prescription and Service Request Form (PSRF)
  2. Fax the completed form to Shared Solutions® at 1-844-257-6127

Patients can call 1-800-887-8100, Monday–Friday, 8 am–6 pm CT.